GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeOne Medicines Ltd (HKSE:06160) » Definitions » EV-to-Revenue

BeOne Medicines (HKSE:06160) EV-to-Revenue : 7.07 (As of Jun. 28, 2025)


View and export this data going back to 2018. Start your Free Trial

What is BeOne Medicines EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, BeOne Medicines's enterprise value is HK$229,808 Mil. BeOne Medicines's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was HK$32,512 Mil. Therefore, BeOne Medicines's EV-to-Revenue for today is 7.07.

The historical rank and industry rank for BeOne Medicines's EV-to-Revenue or its related term are showing as below:

HKSE:06160' s EV-to-Revenue Range Over the Past 10 Years
Min: 4.26   Med: 23.03   Max: 9065.99
Current: 7.01

During the past 12 years, the highest EV-to-Revenue of BeOne Medicines was 9065.99. The lowest was 4.26. And the median was 23.03.

HKSE:06160's EV-to-Revenue is ranked better than
52.01% of 996 companies
in the Biotechnology industry
Industry Median: 7.685 vs HKSE:06160: 7.01

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2025-06-28), BeOne Medicines's stock price is HK$147.40. BeOne Medicines's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 was HK$23.31. Therefore, BeOne Medicines's PS Ratio for today is 6.32.


BeOne Medicines EV-to-Revenue Historical Data

The historical data trend for BeOne Medicines's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BeOne Medicines EV-to-Revenue Chart

BeOne Medicines Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 63.39 18.61 13.42 6.73 4.76

BeOne Medicines Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.29 4.39 6.71 4.76 6.67

Competitive Comparison of BeOne Medicines's EV-to-Revenue

For the Biotechnology subindustry, BeOne Medicines's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BeOne Medicines's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BeOne Medicines's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where BeOne Medicines's EV-to-Revenue falls into.


;
;

BeOne Medicines EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

BeOne Medicines's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=229808.429/32511.657
=7.07

BeOne Medicines's current Enterprise Value is HK$229,808 Mil.
BeOne Medicines's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$32,512 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BeOne Medicines  (HKSE:06160) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

BeOne Medicines's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=147.40/23.31
=6.32

BeOne Medicines's share price for today is HK$147.40.
BeOne Medicines's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$23.31.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BeOne Medicines EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of BeOne Medicines's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


BeOne Medicines Business Description

Address
c/o BeOne Medicines I GmbH, Aeschengraben 27, 21st Floor, Basel, CHE, 4051
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.
Executives
Baker Felix James 2201 Interest of corporation controlled by you
Baker Julian Charles 2201 Interest of corporation controlled by you
Baker Bros. Advisors (gp) Llc 2201 Interest of corporation controlled by you
Baker Brothers Life Sciences Capital, L.p. 2201 Interest of corporation controlled by you
Jpmorgan Chase & Co. 2502 Approved lending agent
Oyler John Victor 2101 Beneficial owner
The Capital Group Companies, Inc. 2201 Interest of corporation controlled by you
Hhlr Advisors, Ltd. 2102 Investment manager
Hhlr Fund, L.p. 2101 Beneficial owner
Amgen Inc. 2101 Beneficial owner
Hillhouse Capital Advisors, Ltd. 2102 Investment manager
Gaoling Fund, L.p. 2101 Beneficial owner
Fidelity Management & Research Company
Fmr Co., Inc.

BeOne Medicines Headlines

No Headlines